Reimagining Nuclear Medicine — Dr. Stephen Moran, Ph.D., Global Program Head, Neuroendocrine Tumors & Other Radiosensitive Cancers, Advanced Accelerator Applications, Novartis
Dr. Stephen Moran, Ph.D., is Global Program Head, Neuroendocrine Tumors & Other Radiosensitive Cancers, for Advanced Accelerator Applications (AAA — https://www.adacap.com/), a Novartis company and also a member of the Oncology Development Unit Leadership Team at Novartis.
Prior to joining AAA, Dr. Moran was Global Head of Novartis Strategy, where he played a key role in defining the company’s strategy, prioritizing critical actions needed to deliver on the mission to discover new ways to extend and improve peoples’ lives. He also led numerous strategic initiatives, including gene therapy (AveXis, now Novartis Gene Therapies), RNA therapeutics (The Medicines Company), precision medicine and digital strategies.